id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2018-P-3672-0005,FDA,FDA-2018-P-3672,Suitability Petition Approval Letter from FDA CVM to  from Zoetis Inc.,Other,Approval,2018-12-21T05:00:00Z,2018,12,2018-12-21T05:00:00Z,,2018-12-21T16:06:33Z,,0,0,09000064839bef4a
FDA-2018-P-3672-0001,FDA,FDA-2018-P-3672,Suitability Petition from Zoetis Inc.,Other,Petition(s),2018-09-28T04:00:00Z,2018,9,2018-09-28T04:00:00Z,2019-03-27T03:59:59Z,2018-09-28T11:31:55Z,,0,0,090000648377d7ae
FDA-2018-P-3672-0002,FDA,FDA-2018-P-3672,Acknowledgment Letter from FDA DDM to Zoetis lnc.,Other,Acknowledgement Letter/Receipt,2018-09-28T04:00:00Z,2018,9,2018-09-28T04:00:00Z,,2018-09-28T11:32:21Z,,0,0,090000648377d867
FDA-2018-P-3672-0003,FDA,FDA-2018-P-3672,"Attachment 1. Pioneer Product Label - Nicarb• (nicarbazin) 25% Type A Medicated Article, NADA 009-476, Phibro Animal Health Corporation re: Suitability Petition from Zoetis Inc.",Supporting & Related Material,Background Material,2018-09-28T04:00:00Z,2018,9,,,2018-09-28T11:33:06Z,,0,0,090000648377d86b
FDA-2018-P-3672-0004,FDA,FDA-2018-P-3672,"Attachment 2. Proposed Generic Product Label (Draft) - Generic ""Nkarbazin 25% Type A Medicated Article,""Zoetls Inc re: Suitability Petition from Zoetis Inc.",Supporting & Related Material,Background Material,2018-09-28T04:00:00Z,2018,9,,,2018-09-28T11:33:23Z,,0,0,090000648377d86c